REG - Hikma Pharmaceutical - Director/PDMR Shareholding
15/03/2022 11:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220315:nRSO8299Ea&default-theme=true
RNS Number : 8299E Hikma Pharmaceuticals Plc 15 March 2022
Hikma Pharmaceuticals PLC - EIP C Vesting
LONDON, 15 March 2022: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons
Discharging Managerial Responsibility ("PDMR") have received shares as a
result of the vesting of their conditional share awards which were granted on
12 March 2019 under the 2014 Executive Incentive Plan ("EIP") Element C.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. All Shares were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 38,862
d) Aggregated information
- Volume
- Price 38,862
£0.00
- Total £0.00
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Siggi Olafsson
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. 16,299 Shares were sold to cover tax
and the remainder were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 26,377
Price(s): £19.88
Volume(s): 16,299
d) Aggregated information
- Volume
- Price 42,676
£19.88
- Total £324,024.12
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Siggi Olafsson
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under a bespoke arrangement in respect of the first year of service
only that operates on the same basis as Element C of the 2014 Executive
Incentive Plan (EIP). 27,498 Shares were sold to cover tax and the remainder
were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 44,502
Price(s): £19.88
Volume(s): 27,498
d) Aggregated information
- Volume
- Price 72,000
£19.88
- Total £546,660.24
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. All Shares were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 26,514
d) Aggregated information
- Volume
- Price 26,514
£0.00
Total £0.00
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Riad Mishlawi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. All Shares were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 23,030
d) Aggregated information
- Volume
- Price 23,030
£0.00
- Total £0.00
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Majda Labadi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Majda Labadi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. All Shares were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 12,064
d) Aggregated information
- Volume
- Price 12,064
£0.00
- Total £0.00
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Bassam Kanaan
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. All Shares were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 19,195
d) Aggregated information
- Volume
- Price 19,195
£0.00
- Total £0.00
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. All Shares were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 17,710
d) Aggregated information
- Volume
- Price 17,710
£0.00
- Total £0.00
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Brian Hoffmann
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Brian Hoffmann
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. 4,310 Shares were sold to cover tax and
the remainder were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 6,975
Price(s): £19.88
Volume(s): 4,310
d) Aggregated information
- Volume
- Price 11,285
£19.88
- Total £85,682.80
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Susan Ringdal
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. 4,820 Shares were sold to cover tax
and the remainder were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 5,383
Price(s): £19.88
Volume(s): 4,820
d) Aggregated information
- Volume
- Price 10,203
£19.88
- Total £95,821.60
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Henriette Nielsen
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Henriette Nielsen
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Shares acquired from the vesting of conditional awards on
14 March 2022 under the EIP Element C. 2,670 Shares were sold to cover tax
and the remainder were retained.
c) Price(s) and volume(s) Price(s): £nil
Volume(s): 4,320
Price(s): £19.88
Volume(s): 2,670
d) Aggregated information
- Volume
- Price 6,990
£19.88
- Total £53,079.60
e) Date of the transaction 14 March 2022
f) Place of the transaction London Stock Exchange (XLON)
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
15 March 2022
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBGGDXRUBDGDURecent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement